% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Scuteri:156003,
      author       = {Scuteri, Damiana and Cassano, Roberta and Trombino, Sonia
                      and Russo, Rossella and Mizoguchi, Hirokazu and Watanabe,
                      Chizuko and Hamamura, Kengo and Katsuyama, Soh and Komatsu,
                      Takaaki and Morrone, Luigi Antonio and Rombolà, Laura and
                      Adornetto, Annagrazia and Laganà, Annarita S and
                      Corasaniti, Maria Tiziana and Tonin, Paolo and Sakurada,
                      Shinobu and Sakurada, Tsukasa and Nicotera, Pierluigi and
                      Bagetta, Giacinto},
      title        = {{D}evelopment and {T}ranslation of {N}ano{BEO}, a
                      {N}anotechnology-{B}ased {D}elivery {S}ystem of {B}ergamot
                      {E}ssential {O}il {D}eprived of {F}urocumarins, in the
                      {C}ontrol of {A}gitation in {S}evere {D}ementia.},
      journal      = {Pharmaceutics},
      volume       = {13},
      number       = {3},
      issn         = {1999-4923},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DZNE-2021-01135},
      pages        = {379},
      year         = {2021},
      abstract     = {Dementia is one of the most common causes of disability
                      worldwide characterized by memory loss, cognitive
                      impairment, and behavioral and psychological symptoms
                      (BPSD), including agitation. Treatment of the latter
                      consists of the off-label use of harmful atypical
                      antipsychotics, though a significant reduction is afforded
                      by pain control. The use of an essential oil endowed with
                      analgesic properties and devoid of toxicity would represent
                      an important option for the management of agitation in
                      dementia. Therefore, the aim of this study was to engineer a
                      nanotechnology delivery system based on solid lipid
                      nanoparticles loaded with bergamot essential oil (BEO) and
                      devised in the pharmaceutical form of an odorless cream
                      (NanoBEO) to confirm its analgesic efficacy for further
                      development and application to control agitation in
                      dementia. BEO has proven strong antinociceptive and
                      anti-allodynic properties and, in its bergapten-free form,
                      it is completely devoid of phototoxicity. NanoBEO has been
                      studied in vivo confirming the previously reported analgesic
                      activity of BEO to which is now added its anti-itching
                      properties. Due to the nanotechnology delivery system, the
                      stability of titrated BEO components is guaranteed. Finally,
                      the latter invention, currently under patent consideration,
                      is smell-devoid allowing efficacy and safety to be
                      established in double-blind clinical trials; until now the
                      latter studies have been impeded in aromatherapy by the
                      strong odor of essential oils. A clinical trial NCT04321889
                      has been designed to provide information about the efficacy
                      and safety of NanoBEO on agitation and pain in patients
                      suffering from severe dementia.},
      keywords     = {BPSD (Other) / agitation (Other) / dementia (Other) /
                      essential oil of bergamot (Other) / nanotechnology delivery
                      system (Other) / pain (Other)},
      cin          = {AG Nicotera},
      ddc          = {610},
      cid          = {I:(DE-2719)5000018},
      pnm          = {351 - Brain Function (POF4-351)},
      pid          = {G:(DE-HGF)POF4-351},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:33809385},
      pmc          = {pmc:PMC7999378},
      doi          = {10.3390/pharmaceutics13030379},
      url          = {https://pub.dzne.de/record/156003},
}